Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2015

Open Access 01-12-2015 | Research

A conceptual disease model for adult Pompe disease

Authors: Tim A. Kanters, W. Ken Redekop, Maureen P.M.H. Rutten-Van Mölken, Michelle E. Kruijshaar, Deniz Güngör, Ans T. van der Ploeg, Leona Hakkaart

Published in: Orphanet Journal of Rare Diseases | Issue 1/2015

Login to get access

Abstract

Background

Studies in orphan diseases are, by nature, confronted with small patient populations, meaning that randomized controlled trials will have limited statistical power. In order to estimate the effectiveness of treatments in orphan diseases and extrapolate effects into the future, alternative models might be needed. The purpose of this study is to develop a conceptual disease model for Pompe disease in adults (an orphan disease). This conceptual model describes the associations between the most important levels of health concepts for Pompe disease in adults, from biological parameters via physiological parameters, symptoms and functional indicators to health perceptions and final health outcomes as measured in terms of health-related quality of life.

Methods

The structure of the Wilson-Cleary health outcomes model was used as a blueprint, and filled with clinically relevant aspects for Pompe disease based on literature and expert opinion. Multiple observations per patient from a Dutch cohort study in untreated patients were used to quantify the relationships between the different levels of health concepts in the model by means of regression analyses.

Results

Enzyme activity, muscle strength, respiratory function, fatigue, level of handicap, general health perceptions, mental and physical component scales and utility described the different levels of health concepts in the Wilson-Cleary model for Pompe disease. Regression analyses showed that functional status was affected by fatigue, muscle strength and respiratory function. Health perceptions were affected by handicap. In turn, self-reported quality of life was affected by health perceptions.

Conclusions

We conceptualized a disease model that incorporated the mechanisms believed to be responsible for impaired quality of life in Pompe disease. The model provides a comprehensive overview of various aspects of Pompe disease in adults, which can be useful for both clinicians and policymakers to support their multi-faceted decision making.
Appendix
Available only for authorised users
Literature
1.
Wilcken B. Rare diseases and the assessment of intervention: What sorts of clinical trials can we use? J Inherit Metab Dis. 2001;24:291–8.CrossRefPubMed
2.
Garau M, Mestre-Ferrandiz J. Access mechanisms for orphan drugs: A comparative study of selected European countries. OHE Briefing. 2009;52:1–30.
3.
Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: Focus on the underlying pharmacoeconomic evaluations. Clin Ther. 2010;32:1651–61.CrossRefPubMed
4.
Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA. 1995;273:59–65.CrossRefPubMed
5.
6.
Van den Hout JMP, Reuser AJJ, De Klerk JBC, Arts WF, Smeitink JAM, Van der Ploeg AT. Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis. 2001;24:266–74.CrossRefPubMed
7.
Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671–676e2.CrossRefPubMed
8.
9.
Engel AG, Gomez MR. Acid maltase levels in muscle in heterozygous acid maltase deficiency and in non-weak and neuromuscular disease controls. J Neurol Neurosurg Psychiatry. 1970;33:801–4.PubMedCentralCrossRefPubMed
10.
Rosenow EC, Engel AG. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med. 1978;64:485–91.CrossRefPubMed
11.
Güngör D, De Vries JM, Hop WCJ, Reuser AJJ, Van Doorn PA, Van der Ploeg AT, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34.PubMedCentralCrossRefPubMed
12.
Van den Hout H, Reuser AJJ, Vulto AG, Loonen MCB, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human [alpha]-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397–8.CrossRefPubMed
13.
Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362:1396–406.CrossRefPubMed
14.
15.
Güngör D, Kruijshaar ME, Plug L, D’Agostino RB, Hagemans MLC, Van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: Results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.PubMedCentralCrossRefPubMed
16.
Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: A report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Making. 2012;32:678–89.CrossRefPubMed
17.
Kanters TA, Hagemans MLC, Van der Beek NAME, Rutten FFH, Van der Ploeg AT, Hakkaart L. Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis. 2011;34:1045–52.PubMedCentralCrossRefPubMed
18.
Wooldridge JM. Econometric analysis of cross section and panel data. Cambridge, Massachusetts: The MIT Press; 2002.
19.
Hagemans MLC, Winkel LPF, Van Doorn PA, Hop WJC, Loonen MCB, Reuser AJJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128:671–7.CrossRefPubMed
20.
Van der Beek NAME, Van Capelle CI, Van der Velden-Van Etten KI, Hop WCJ, Van den Berg B, Reuser AJJ, et al. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab. 2011;104:129–36.CrossRefPubMed
21.
Wokke JHJ, Escolar DM, Pestronk A, Jaffe KM, Carter GT, Van den Berg LH, et al. Clinical features of late‐onset Pompe disease: A prospective cohort study. Muscle Nerve. 2008;38:1236–45.CrossRefPubMed
22.
De Vries JM, Van der Beek NAME, Hop WCJ, Karstens FPJ, Wokke JH, De Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: An open-label single-center study. Orphanet J Rare Dis. 2012;7:73.PubMedCentralCrossRefPubMed
23.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl. 1993;16:5–40.CrossRefPubMed
24.
Hagemans MLC, Van Schie SPM, Janssens ACJW, Van Doorn PA, Reuser AJJ, Van der Ploeg AT. Fatigue: An important feature of late-onset Ppompe disease. J Neurol. 2007;254:941–5.PubMedCentralCrossRefPubMed
25.
De Vries JM, Hagemans MLC, Bussmann JBJ, Van der Ploeg AT, van Doorn PA. Fatigue in neuromuscular disorders: Focus on Guillain–Barré syndrome and Pompe disease. Cell Mol Life Sci. 2010;67:701–13.PubMedCentralCrossRefPubMed
26.
Mellies U, Lofaso F. Pompe disease: A neuromuscular disease with respiratory muscle involvement. Respir Med. 2009;103:477–84.CrossRefPubMed
27.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–3.CrossRefPubMed
28.
Merkies ISJ, Schmitz PIM, Van der Meché FGA, Samijn J, Van Doorn PA. Psychometric evaluation of a new handicap scale in immune‐mediated polyneuropathies. Muscle Nerve. 2002;25:370–7.CrossRefPubMed
29.
Hagemans MLC, Laforet P, Hop WJC, Merkies ISJ, Van Doorn PA, Reuser AJJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam handicap scale. Neuromuscular Disord. 2007;17:537–43.CrossRef
30.
Group EQ. EuroQol: A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.CrossRef
31.
Hagemans MLC, Janssens A, Winkel LPF, Sieradzan KA, Reuser AJJ, Van Doorn PA, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology. 2004;63:1688–92.CrossRefPubMed
32.
Ware JE, Kosinski M. SF-36 physical & mental health summary scales: A manual for users of version 1. Lincoln, RI: QualityMetric Incorporated; 2001.
33.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
34.
Lamers LM, McDonnell J, Stalmeier PFM, Krabbe PFM, Busschbach JJV. The Dutch tariff: Results and arguments for an effective design for national EQ‐5D valuation studies. Health Econ. 2006;15:1121–32.CrossRefPubMed
35.
Hagemans MLC, Winkel LPF, Hop WCJ, Reuser AJJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64:2139–41.CrossRefPubMed
36.
Herzog A, Hartung R, Reuser AJJ, Hermanns P, Runz H, Karabul N, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: Molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis. 2012;7:35.PubMedCentralCrossRefPubMed
37.
Van der Beek NAME, Hagemans MLC, Reuser AJJ, Hop WCJ, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscular Disord. 2009;19:113–7.CrossRef
38.
Van der Beek NAME, De Vries JM, Hagemans MLC, Hop WCJ, Kroos MA, Wokke JHJ, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: A nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.PubMedCentralCrossRefPubMed
39.
Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM. 2005;98:829–36.CrossRefPubMed
40.
Güngör D, De Vries JM, Brusse E, Kruijshaar ME, Hop WCJ, Murawska M, et al. Enzyme replacement therapy and fatigue in adults with Pompe disease. Mol Genet Metab. 2013;109:174–8.CrossRefPubMed
41.
Güngör D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SCA, et al. Quality of life and participation in the daily life activities of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. In: Güngör D, editor. Survival, quality of life and effects of enzyme replacement therapy in adults with Pompe disease. Enschede: Ipskamp Drukkers; 2013. p. 111–23.
42.
Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review. J Neurol. 2013;260:951–9.CrossRefPubMed
Metadata
Title
A conceptual disease model for adult Pompe disease
Authors
Tim A. Kanters
W. Ken Redekop
Maureen P.M.H. Rutten-Van Mölken
Michelle E. Kruijshaar
Deniz Güngör
Ans T. van der Ploeg
Leona Hakkaart
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2015
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-015-0334-6

Other articles of this Issue 1/2015

Orphanet Journal of Rare Diseases 1/2015 Go to the issue

Research

Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study

Research

Clinical profile of patients with ATP1A3 mutations in Alternating Hemiplegia of Childhood—a study of 155 patients

Review

Primary erythromelalgia: a review

Research

Elevated risk of thrombophilia in agenesis of the vena cava as a factor for deep vein thrombosis

Letter to the Editor

Rare diseases and orphan drugs: 500 years ago

Research

Clinical outcome, biochemical and therapeutic follow-up in 14 Austrian patients with Long-Chain 3-Hydroxy Acyl CoA Dehydrogenase Deficiency (LCHADD)